Industry Outlook
Sinusitis treatment drugs market valued at about USD 2.1 billion in 2019 and expected to reach about USD 2.9 billion by 2029 with an estimated CAGR of 3% during the forecast period of 2021 to 2029.Sinustis is defined as an inflammation of paranasal sinuses. Key causes include autoimmune reactions, allergy or physical obstruction. Sinusitis could be acute (symptoms lasting for 4 weeks) or chronic (symptoms extending more than 12 weeks). Acute sinusitis usually is caused by virus and effective method of treatment were nasal irrigation. For chronic sinusitis, patients were prescribed with antibiotics, topical and corticosteroids, and other medications. Sinusitis affects nearly 40% of the US population, with annual treatment costs of $ 8.6 million. Such high prevalence especially among the urban population has been the prime driving factor. Increasing pollution due to urbanization, air and water pollution has made the people more vulnerable to bacteria and viruses causing sinusitis. In addition, there has been significant transformation in the diagnosis of sinusitis from merely physical examination to application of endoscopy and computed tomography (CT) have improved the process of diagnosis and eventually increased the diagnosis rate.
Decongestant & mucolytic agents contributed to the highest revenue in the year 2019 and is also expected to perform consistently and maintain it’s significant even during the forecast period of 2021 to 2029. The increasing awareness among the public has encouraged to sought for the treatment quite early leading to first line of treatment including nasal saline irrigation and nasal corticosteroid sprays. This also led to increased percent of population being diagnosed for sinusitis. Emerging technologies withrespect to drug delivery has eased the process of treatment. In term of therapeutic options antibiotics accounted to the fastest growth during the forecast period of 2021 to 2029. There has been keen focus among the pharma companies to invest in novel antibiotics that were efficient with lesser side effects. National Institute of Health (NIH) recorded that in 1000 patients, the incidence of acute sinusitis is 15 to 40 episodes per year. This makes it the second most common infections across the globe.
In year 2019, decongestant & mucolytic agents accounted for the largest market share and expected to maintain its dominance throughout the forecast period.The key factors responsible for market growth are first line of action for non-infectious sinusitis, upcoming novel technologies of drug delivery, and increasing patient-awareness has assisted the growth in disease diagnosis rate.During the forecast period from 2021 to 2029, antibiotics observed as fastest growing segment due to key market drivers such as developing diagnostics technologies.As per the latest research quote published by National Institute of Health (NIH), the incidence of acute sinusitis is 15 to 40 episodes in 1000 patients per year.Acute sinusitis is the second most common infectious disease encountered by general practitioners throughout the globe.
North America topped the revenues for sinusitis treatment drug market. Key factors that can be attributed to the market growth are increased prevalence of sinusitis, increased awareness leading to patients approaching the medical experts for diagnosis and treatment, increased focus on technological innovation that led to efficient delivery of treatment and diagnosis. Interms of growth rate Asia Pacific is expected to witness the highest CAGR from 2021 to 2029. The key reason was increasing urbanization in this region that ultimately led to pollution in APAC region such as China, Indonesia, India, Srilanka and so on. The increasing healthcare infrastructure increased the patient poll turning for diagnosis and treatment. Not to forget that India and China held the largest population in the world.
Historical & Forecast Period
This research report presents the analysis of each segment from 2019 to 2029 considering 2020 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segment are calculated for the forecast period from 2021 to 2029.
Key players included in the report include Pfizer, Inc., Janssen Pharmaceuticals, Abbott Laboratories, GlaxoSmithKline Plc, Sanofi SA, Novartis AG, and Teva Pharmaceutical Industries, Ltd. among others.
Key questions answered in this report
This product will be delivered within 2 business days.
Sinusitis treatment drugs market valued at about USD 2.1 billion in 2019 and expected to reach about USD 2.9 billion by 2029 with an estimated CAGR of 3% during the forecast period of 2021 to 2029.Sinustis is defined as an inflammation of paranasal sinuses. Key causes include autoimmune reactions, allergy or physical obstruction. Sinusitis could be acute (symptoms lasting for 4 weeks) or chronic (symptoms extending more than 12 weeks). Acute sinusitis usually is caused by virus and effective method of treatment were nasal irrigation. For chronic sinusitis, patients were prescribed with antibiotics, topical and corticosteroids, and other medications. Sinusitis affects nearly 40% of the US population, with annual treatment costs of $ 8.6 million. Such high prevalence especially among the urban population has been the prime driving factor. Increasing pollution due to urbanization, air and water pollution has made the people more vulnerable to bacteria and viruses causing sinusitis. In addition, there has been significant transformation in the diagnosis of sinusitis from merely physical examination to application of endoscopy and computed tomography (CT) have improved the process of diagnosis and eventually increased the diagnosis rate.
Decongestant & mucolytic agents contributed to the highest revenue in the year 2019 and is also expected to perform consistently and maintain it’s significant even during the forecast period of 2021 to 2029. The increasing awareness among the public has encouraged to sought for the treatment quite early leading to first line of treatment including nasal saline irrigation and nasal corticosteroid sprays. This also led to increased percent of population being diagnosed for sinusitis. Emerging technologies withrespect to drug delivery has eased the process of treatment. In term of therapeutic options antibiotics accounted to the fastest growth during the forecast period of 2021 to 2029. There has been keen focus among the pharma companies to invest in novel antibiotics that were efficient with lesser side effects. National Institute of Health (NIH) recorded that in 1000 patients, the incidence of acute sinusitis is 15 to 40 episodes per year. This makes it the second most common infections across the globe.
In year 2019, decongestant & mucolytic agents accounted for the largest market share and expected to maintain its dominance throughout the forecast period.The key factors responsible for market growth are first line of action for non-infectious sinusitis, upcoming novel technologies of drug delivery, and increasing patient-awareness has assisted the growth in disease diagnosis rate.During the forecast period from 2021 to 2029, antibiotics observed as fastest growing segment due to key market drivers such as developing diagnostics technologies.As per the latest research quote published by National Institute of Health (NIH), the incidence of acute sinusitis is 15 to 40 episodes in 1000 patients per year.Acute sinusitis is the second most common infectious disease encountered by general practitioners throughout the globe.
North America topped the revenues for sinusitis treatment drug market. Key factors that can be attributed to the market growth are increased prevalence of sinusitis, increased awareness leading to patients approaching the medical experts for diagnosis and treatment, increased focus on technological innovation that led to efficient delivery of treatment and diagnosis. Interms of growth rate Asia Pacific is expected to witness the highest CAGR from 2021 to 2029. The key reason was increasing urbanization in this region that ultimately led to pollution in APAC region such as China, Indonesia, India, Srilanka and so on. The increasing healthcare infrastructure increased the patient poll turning for diagnosis and treatment. Not to forget that India and China held the largest population in the world.
Historical & Forecast Period
This research report presents the analysis of each segment from 2019 to 2029 considering 2020 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segment are calculated for the forecast period from 2021 to 2029.
Key players included in the report include Pfizer, Inc., Janssen Pharmaceuticals, Abbott Laboratories, GlaxoSmithKline Plc, Sanofi SA, Novartis AG, and Teva Pharmaceutical Industries, Ltd. among others.
Key questions answered in this report
- What are the key market segments in current scenario and in the future by product categories?
- What are the key market segments in current scenario and in the future by regions?
- What is the key impact of Covid 19 over market revenues and market determinants in the medical aesthetics market?
- What are the primary and secondary macro and micro factors influencing the market growth currently and during the forecast period?
- What are the primary and secondary macro and micro factors deterring the market growth currently and during the forecast period?
- How to overcome the current market challenges and leverage the opportunities in each of the market segment?
- Who are the key players in the medical aesthetics market and what are their key product categories and strategies?
- What are the key strategies – mergers/acquisitions/R&D/strategic partnerships etc that companies are deploying to enhance market revenues and growth?
This product will be delivered within 2 business days.
Table of Contents
Chapter 1 Preface1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.4 Assumptions
Chapter 2 Executive Summary
2.1 Global STD Market Portraiture
2.2 Global STD Market, by Treatment Type, 2019 (US$ Mn)
2.3 Global STD Market, by Geography, 2019 (US$ Mn)
2.4 Impact of Covid 19
Chapter 3 Global Sinusitis Treatment Drugs (STD) Market Analysis
3.1 Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.1.1 High Prevalence of Sinusitis
3.2.1.2 Rising Pollution Contributing to Increased Incidence of Sinusitis
3.2.2 Challenges
3.2.2.1 Overuse of Drugs and Excessive Self Medication
3.2.3 Market Opportunities
3.2.3.1 Big Opportunities for New Innovative Treatments
3.3 Attractive Investment Proposition, by Geography, 2019
3.4 Market Positioning: by Key Players in STD Market, 2019
Chapter 4 Global Sinusitis Treatment Drugs (STD) Market, by Treatment Type, 2019-2029 (US$ Mn)
4.1 Overview
4.2 Antibiotics
4.2.1 Cephalosporin Antibiotics
4.2.2 Penicillin/Beta Lactamase Inhibitors
4.2.3 Macrolide Antibiotics
4.2.4 Quinolone Antibiotics
4.3 NSAIDS
4.4 Decongestant & Mucolytic
4.4.1 Imidazoline Derivatives
4.4.2 Antihistamines
4.4.3 Corticosteroids
4.4.4 α₁-adrenergic receptor agonist
4.5 Nasal Irrigation Kits
4.6 Pipeline Analysis
4.6.1 Phase III
4.6.1.1 Omalizumab (F.Hoffman La-Roche AG)
4.6.2 Phase II and I (Tabular Format)
Chapter 5 Global Sinusitis Treatment Drugs (STD) Market, by Geography, 2019-2029(US$ Mn)
5.1 Overview
5.2 North America
5.2.1 North America STD Market, by Treatment Type, 2019-2029(US$ Mn)
5.2.2 North America STD Market, by Country, 2019-2029(US$ Mn)
5.2.2.1 U.S.
5.2.2.2 Canada
5.3 Europe
5.3.1 Europe STD Market, by Treatment Type, 2019-2029(US$ Mn)
5.3.2 Europe STD Market, by Region/Country, 2019-2029(US$ Mn)
5.3.2.1 U.K.
5.3.2.2 Germany
5.3.2.3 Rest of Europe
5.4 Asia Pacific
5.4.1 Asia Pacific STD Market, by Treatment Type, 2019-2029(US$ Mn)
5.4.2 Asia Pacific STD Market, by Region/Country, 2019-2029(US$ Mn)
5.4.2.1 Japan
5.4.2.2 China
5.4.2.3 Rest of Asia Pacific
5.5 Latin America (LATAM)
5.5.1 Latin America STD Market, by Treatment Type, 2019-2029(US$ Mn)
5.5.2 Latin America STD Market, by Region/Country, 2019-2029(US$ Mn)
5.5.2.1 Brazil
5.5.2.2 Mexico
5.5.2.3 Rest of Latin America
5.6 Middle East & Africa (MEA)
5.6.1 Middle East & Africa STD Market, by Treatment Type, 2019-2029(US$ Mn)
5.6.2 Middle East & Africa STD Market, by Region, 2019-2029(US$ Mn)
5.6.2.1 GCC
5.6.2.2 Rest of Middle East & Africa
Chapter 6 Company Profiles
6.1 Pfizer, Inc.
6.2 Abbott Laboratories, Inc.
6.3 Janssen Pharmaceuticals, Inc.
6.4 GlaxoSmithkline, Plc.
6.5 Sanofi SA
6.6 Sandoz International GmbH (a subsidiary of Novartis International AG)
6.7 Bayer AG
6.8 Merck & Co., Inc.
6.9 Sun Pharmaceutical Industries Ltd.
6.10 Teva Pharmaceutical Industries Ltd.
* STD - Sinusitis Treatment DrugsList of Tables
Table 1 Global Sinusitis Treatment Drugs (STD) Market Portraiture
Table 2 Global STD Market, by Treatment Type, 2019-2029(US$ Mn)
Table 3 Global Antibiotics Market for Sinusitis Treatment, 2019-2029(US$ Mn)
Table 4 Global Decongestant & Mucolytic Market for Sinusitis Treatment, 2019-2029(US$ Mn)
Table 5 Global STD Market, by Geography, 2019-2029(US$ Mn)
Table 6 North America STD Market, by Treatment Type, 2019-2029(US$ Mn)
Table 7 North America STD Market, by Country, 2019-2029(US$ Mn)
Table 8 Europe STD Market, by Treatment Type, 2019-2029(US$ Mn)
Table 9 Europe STD Market, by Region/Country, 2019-2029(US$ Mn)
Table 10 Asia Pacific STD Market, by Treatment Type, 2019-2029(US$ Mn)
Table 11 Asia Pacific STD Market, by Region/Country, 2019-2029(US$ Mn)
Table 12 Latin America STD Market, by Treatment Type, 2019-2029(US$ Mn)
Table 13 Latin America STD Market, by Region/Country, 2019-2029(US$ Mn)
Table 14 Middle East & Africa STD Market, by Treatment Type, 2019-2029(US$ Mn)
Table 15 Middle East & Africa STD Market, by Region, 2019-2029(US$ Mn)
Table 16 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 17 Abbott Laboratories, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 18 Jansenn Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 19 GlaxoSmithkline, Plc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 20 Sanofi SA: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 21 Sandoz International GmbH (a subsidiary of Novartis International AG): Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 22 Bayer AG: Company Snapshot (Business Description; Financial Performance; Product Portfolio; Key Developments)
Table 23 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; Key Developments)
Table 24 Sun Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; Key Developments)
Table 25 Teva Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; Key Developments)
Companies Mentioned
- Pfizer Inc.
- Janssen Pharmaceuticals
- Abbott Laboratories
- GlaxoSmithKline Plc
- Sanofi SA
- Novartis AG
- Teva Pharmaceutical Industries
